WO1993019053A1 - Derive de depsipeptide, production et utilisation - Google Patents
Derive de depsipeptide, production et utilisation Download PDFInfo
- Publication number
- WO1993019053A1 WO1993019053A1 PCT/JP1993/000286 JP9300286W WO9319053A1 WO 1993019053 A1 WO1993019053 A1 WO 1993019053A1 JP 9300286 W JP9300286 W JP 9300286W WO 9319053 A1 WO9319053 A1 WO 9319053A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meleu
- group
- production example
- lac
- nmr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
Definitions
- the present invention relates to a novel depeptide peptide having anthelmintic activity.
- the depsipeptide derivative (I) which is the target compound of the present invention can be represented by the following general formula.
- A is a benzyl group having a suitable substituent or a phenyl group which may have a suitable substituent
- a a is a benzyl group which may have a suitable substituent or A phenyl group which may have a substituent
- B and D each represent a lower alkyl group
- C represents a hydrogen or a lower alkyl group
- the target compound depsipeptide derivative (I) can be produced by the following method.
- R is a hydrogen or amino protecting group
- A is a benzyl group with or without a lower alkoxy group
- a 2 is a nitro group or a benzyl group having a nitro group and a lower alkoxy group
- a 3 is benzyl group
- a 4 is mono- or di-lower Arukiruamino base Njiru group having Amino group or Amino group and a lower alkoxy group or a mono- or di-lower ⁇ Rukiruamino
- a 5 has a cyclic amino group or a benzyl group having a cyclic amino group and a lower alkoxy group
- a 6 has a hydroxyl group or a benzyl group having a hydroxyl group and a lower alkoxy group
- a 7 has a lower alkoxy group. Benzyl group).
- amino acids, peptides, protecting groups, condensing agents, etc. are referred to by the abbreviation by IUPAC-IBB (Biochemical Nomenclature Committee) used in the art for ⁇ !.
- amino acids and their residues refer to compounds and residues in the L-configuration and compounds and residues in the D-configuration. It is indicated by the following description.
- 3,4-DMAPh c 3-[(3,4-bis (dimethylamino) phenyl] -2-hydroxyfif: Lnyl] probion »[ ⁇ ⁇ [3,4-bis (dimethylamino) phenyl]? L »]
- m-FPhLac 3- (3-Fluorophane; Lnyl) -2-hydroxypropion »
- the non-reactive salts of compound (I) include conventional non-toxic salts, that is, salts with various bases and acid addition salts. More specifically, inorganic bases such as alkali metal salts (eg, sodium salts, potassium salts, cesium salts, etc.), alkaline earth metal salts (eg, calcium salts, magnesium salts, etc.), and ammonium salts of Organic salts such as salts, organic amine salts (eg, triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N, ⁇ '-dibenzylethylenediamine salt, etc.) Salts with bases, inorganic acid addition salts (eg, hydrochloride, hydrobromide, sulfate, phosphate, etc.), organic carboxylic acid addition salts or organic sulfonic acid addition salts (eg, formate, acetate, trifluoromethane) Acetate, maleate
- “Lower” means the range of 1-6, preferably 1-4 atoms, unless otherwise indicated. .
- substituent in the “benzyl group having a substituent”, the “phenyl group optionally having a substituent” and the “benzyl group optionally having a substituent” include hydroxy, lower alkoxy, Lower alkoxy, lower alkoxy, lower alkoxy, lower alkoxy, lower alkoxy, halogen, lower alkyl, amino, cyclic amino, nitro, and halogen such as fluorine, chlorine, bromine, and iodine. Or it may have two or more.
- lower alkisoles include 1 to 6 ⁇ atoms such as, for example, methyl, ethyl, ⁇ -propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc. And a straight-chain or branched-chain alkyl group.
- lower alkoxy examples include groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentyloxy, isopentyloxy, hexyloxy, and the like.
- lower alkoxy lower alkoxy examples include groups such as methoxymethoxy, methoxyethoxy, methoxypropoxy and ethoxyisopropoxy.
- lower alkoxy lower alkoxy lower alkoxy J examples include methoxy
- groups such as methoxhetoxy, methoxhetoxetoxy, methoxetoxypropoxy, and ethoxymethoxyisopropoxy.
- cyclic amino group refers to an aromatic or alicyclic group having at least one nitrogen atom as a hetero atom, and may be a saturated or unsaturated, monocyclic or condensed polycyclic group. And the ring may further contain one or more hetero atoms such as a nitrogen atom, an oxygen atom and a sulfur atom. Further, the cyclic amino group may be a spiro group or a bridged ring.
- the number of atoms constituting this cyclic amino group is not particularly limited. For example, in the case of a monocyclic group, the number of atoms is 3 to 8 members, and in the case of a bicyclic group, what is it? ⁇ 1 is a one-membered ring.
- cyclic amino groups include: 1-azetidinyl group, pyrrolidino group, 2-pyrroline-11-inole group, 1-pyrrolyl group, piperidino group, 1,4-dihydroxypyridine-11-yl group, 1,2 Saturated or unsaturated monocyclic groups containing one nitrogen atom as a heteroatom such as 1,5-, 6-tetrahydropyridine-11-inole group, homopiperidino group, 1-imidazolidinyl group, 1-imidazolyl group, 1- Pyrazolyl group, 1-triazolinole group, 1-tetrazolinole group, 1-piperazinyl group, 1-homopiperazinyl group, 1,2-dihydropyridazine-11-inole group, 1,2-dihydropyrimidine-11-yl group, perhydropyrimidine Saturated or unsaturated containing two or more nitrogen atoms as hetero atoms such as, a syn-111-isole group,
- hetero atom such as m3 ⁇ 4-type group, oxazolidine-13-inole group, 2,3-dihydroisoxazole-2-yl group, morpholino group, 1 to 3 nitrogen atoms and 1 to 2 oxygen atoms
- Hetero atoms such as saturated or unsaturated monocyclic group, thiazolidine-1-yl group, isothiazoline-2-yl group, thiomorpholino group, containing 1 to 3 nitrogen atoms and 1 to 2 sulfur atoms Or unsaturated ⁇ formula groups containing indole, 1,2-dihydrobenzenesmidazole-1,1-inole groups, perhydropyro [1,2-a] pyrazine-12-inole groups, etc.
- Condensed cyclic groups such as 2-azaspiro [4,5] decane-2-yl group, and bridging heterotypes such as 7-azabicyclo [2,2,1] heptane-17-yl group And cyclic groups.
- lower alkoxy, lower alkyl, amino, and cyclic amino groups are suitable. It may have a substituent, and examples of such a substituent include a mono- or di-substituted lower alkylamino, lower alkenyl group, aralkyl group, aryl group, hydroxy group, hydroxy lower alkyl group, nitro group, A cyano group, a cyclic amino group as described above, a lower alkoxy group as described above, a lower alkoxy lower alkyl group, a halogen atom, a halo lower alkyl group, an amino group, a protected amino group, an amino lower alkyl group, a protected amino group A lower alkyl group, a cyclo lower alkylamino group, and the like.
- the number of these substituents is not particularly limited, but is preferably 1 to 4, and these substituted components may be the same or different. Further, two identical or different substituents may be substituted on the same atom on the cyclic amino group.
- one or two lower alkyl groups such as a methyl group, an ethyl group, an isopropyl group, a ⁇ ! ⁇ -butyl group, an H- and a pentyl group are substituted for an amino group.
- Examples thereof include a methylamino group, an ethylamino group, a dimethylamino group, a dimethylamino group, a di-n-propylamino group, a diisopropylamino group, and a dibutylamino group.
- lower alkenyl group examples include a vinyl group, an aryl group, an isopropyl group and the like.
- aralkylsole group examples include a benzyl group and a 1-phenylethyl group.
- aryl group examples include a phenyl group and a naphthyl group.
- a hydroxy lower alkynole group, an alkoxy lower alkyl group, a halo lower alkyl group, an amino lower alkyl group, and a protected amino lower alkyl group are those in which any atom of the lower alksole group is a hydroxy group or an alkoxy group, respectively.
- amino protective group examples include lower alkanoinole groups such as formyl, acetyl, propionyl, viva leinole, hexanoizole and the like (for example, mono- or di-chloroacetyl, bromoacetyl, dichloroacetyl, trifluoroacetyl, etc.
- Tri) halo (lower) alkanol groups for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, lower alkoxyl carbonyl groups such as tert-butoxycarbonyl, tertiary pentoxycarbonyl, hexyloxycarbonyl, etc .;
- aroyl groups such as benzoyl, toluoyl and naphthoyl; alkenyl groups such as phenylacetyl and phenylpropionyl; lower alkanol groups such as phenyloxycarbonyl and naphthyloxycarbonyl;
- aryloxy (lower) alkanol groups such as phenoxyacetyl, phenyloxypropionyl, etc., aryl glyoxylenole groups such as phenyldalioxyloyl, naphthylglyoxyloyl, etc., for example, benzyl Al
- the above-mentioned amino protecting group includes a protecting group having an action of temporarily protecting an amino group often used in the field of amino acid and peptide chemistry.
- benzyl group substituted by lower alkoxy examples include, for example, 4-methoxybenzyl, 2,4-dimethoxybenzyl, 3,4 dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 2,3,4 — Lower alkoxy-substituted benzyl groups such as trimethoxybenzyl, 21-ethoxybenzyl and 4-hexyloxybenzyl.
- benzyl group substituted with halogen examples include 2-fluorobenzene, 3-fluorobenzyl, 4-fluorobenzyl,, 2-benzobenzene, 4-chlorobenzyl, 2,4-dichlorobenzene, and the like.
- Halogen-substituted benzyl groups such as benzyl, 3,4-dichlorobenzene, 2,6-dichlorobenzyl, 2-bromobenzyl, and 2-bromo-4-benzobenzole. .
- Examples of a "benzyl group substituted with a lower alkyl” include, for example, 4-methylbenzyl, 4-ethylbenzyl, 4-propylbenzyl, and 4-isopropylbenzyl.
- Lower alkyl-substituted benzene groups such as, 4-dimethylbenzyl, 2,4,6-trimethylbenzyl, etc.
- phenyl groups having such substituents include, for example, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 2,3,4-trimethoxyphenyl, 2- Lower alkoxy-substituted phenyl groups such as ethoxyphenyl and 4-hexyloxyphenyl, for example, 2-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,6-dichloro Halogenated phenyl groups such as mouth phenyl, 2-bromophenyl, 2-bromo-4-chloro mouth phenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl Hydroxy-substituted phenyl groups such as, 4-hydroxyphenyl, lower alkoxy and hydro- xyls such as 2- (hydroxymethoxy
- benzyl groups having such substituents include, for example, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 2,3,4-trimethoxybenzyl.
- Lower alkoxy-substituted benzyl groups such as benzyl, 2-ethoxybenzyl, and 4-hexyloxybenzyl, for example, 2-chlorobenzene, 4-chlorobenzyl, 2,4-dichlorobenzyl, and 3,4-dichlorobenzyl Benzene, 2,6-dichlorobenzyl, 2-bromobenzyl, 2-bromo-4-chlorobenzyl, etc., 2-hydroxybenzyl, 3-hydroxybenzyl, 4-hydroxybenzyl, etc. And hydroxy-substituted benzyl groups such as 2- (hydroxy methoxy) benzyl and the like.
- optionally substituted cyclic amino group examples include a pyrrolidino group, a morpholino group, 1-piperazino, 4-methylbiperazino, piperidino and the like.
- the target compound (I) or a salt thereof can be produced by subjecting the compound (II) or a reactive derivative thereof at an amino group or a carboxy group, or a salt thereof to a ring closure reaction.
- the starting compound (11), a reactive derivative thereof or a salt thereof is novel and can be produced by a method described in Production Examples described later or a method similar thereto.
- Examples of the reactive derivative of the amino group of the compound (II) include Schiff's basic imino or an enamine tautomer thereof formed by the reaction of the amino group of the compound with a carbonyl compound such as aldehyde or ketone; A silyl derivative formed by the reaction of an amino group of a compound with a silyl compound such as bis (trimethylsilyl) acetamide, mono (trimethylsilyl) acetamide, bis (trimethylsilyl) urea, etc .; the amino group of the compound and phosphorus trichloride Or derivatives formed by reaction with phosgene.
- Examples of the reactive derivative in the carboxy group of the compound (II) include an acid halide, an acid anhydride, an activated amide, an activated ester and the like.
- Examples of reactive derivatives include: acid chlorides; acid azides; aliphatic carboxylic acids such as acetic acid, propionic acid, butyric acid, and trichloroacetic acid; or aromatic acids such as benzoic acid. Mixed acid anhydrides; symmetrical acid anhydrides and the like.
- These reactive derivatives can be selected from those described above according to the type of the compound (II) to be used. This reaction is carried out by a method usually used for a ring closure reaction, for example, heating or in the presence of a condensing agent.
- the R group of the compound (II) is an amino-protecting group, the amino-protecting group is eliminated before the ring-closure reaction.
- Preferred condensing agents include carbodiimide or a salt thereof [for example, N—N′-dicyclohexyl carbodiimide, N-cyclohexyl-1N′—morpholinoethylcarbodiimide, N-cyclohexyl-1N′— ( 4-Jetylaminocyclohexyl) carbodiimid, N-ethyl-N '-(3-dimethylaminopropyl) carbodiimide or its hydrochloride, diphenylphosphoric azide, decylphosphoric aniside, shirazobis (2-oxo1 , ⁇ '-carbodimidazole, ⁇ , ⁇ '-carbonylbis (2-methylimidazole); ketenimine compounds (for example, pentamethyleneketene-1-cyclohexyl) Silymine, diphenylketene-1-N-cyclohexylimine, etc.); ethoxyacety
- the reaction under this condensing agent is carried out in a conventional organic solvent that does not interfere with the reaction (eg, dichloromethane, methanol, ethanol, propal, acetonitrile, pyridine, N, N-getylformamide,
- the reaction is carried out in 4-methyl-12-pentanone, tetrahydrofuran, benzene, toluene, xylene, or a mixture thereof, and the reaction is not particularly limited, but is usually carried out under cooling or heating.
- the ring closure reaction under heating can be carried out in an organic solvent as described above by heating to a boiling point of the used solvent or lower.
- the target compound (Ia) or a salt thereof can be produced by subjecting the compound (III) or a salt thereof to nitration.
- the starting material compound (III) includes known compounds (JP-A-3-35796) and novel compounds, and these compounds can be produced by the following Production Examples, Examples and methods similar thereto.
- This reaction is carried out by reacting the compound (III) or a salt thereof with a nitrating agent such as nitric acid.
- the reaction is usually bad for the reaction!
- the reaction can also be carried out in a conventional solvent (for example, dichloromethane) which does not exceed ⁇ .
- the reaction is not particularly limited, but is usually performed under cooling to room temperature. It is a substance, and can be produced, for example, by the method described in Production Examples described later. It can be carried out according to the method described in Example 7 described later.
- the target compound (Ib) or a salt thereof can be produced by subjecting the compound (Ia) or a salt thereof to a reduction reaction.
- This reaction can be performed by a conventional method used for reducing nitro to amino, and includes chemical reduction and catalytic reduction.
- Suitable reducing agents used for chemical reduction include metals (eg, tin, zinc, iron, etc.) or metal compounds (eg, chromium chloride, chromium acetate, etc.) and organic or inorganic acids (eg, formic acid, acetic acid, propionic acid, etc.). Trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).
- catalysts used for catalytic reduction include platinum catalysts (for example, platinum plate, platinum sponge, platinum III, colloidal platinum, platinum oxide, platinum wire, etc.) and palladium catalysts (for example, palladium «, noradium black, acid oxide, etc.).
- platinum catalysts for example, platinum plate, platinum sponge, platinum III, colloidal platinum, platinum oxide, platinum wire, etc.
- palladium catalysts for example, palladium «, noradium black, acid oxide, etc.
- Nickel catalysts for example, reduced nickel, oxidized niger, raney-nickel, etc.
- nickel catalysts for example, reduced nickel, oxidized niger, raney-nickel, etc.
- cobalt catalyst eg, reduced cobalt, Raney cobalt, etc.
- iron catalyst eg, reduced iron, Raney iron, etc.
- copper catalyst eg, reduced copper, Raney copper, Ullman copper, etc.
- the reduction is usually performed in a conventional solvent that does not adversely affect the reaction, for example, water, methanol, ethanol, propanol, N, N-dimethylformamide, or a mixture thereof.
- a conventional solvent that does not adversely affect the reaction
- the acids used for the chemical reduction are liquid, they can be used as a solvent.
- Suitable solvents for use in the catalytic reduction include self-solvents and other conventional solvents such as getyl ether, dioxane, tetrahydrofuran and the like, or mixtures thereof.
- the reaction for the reduction is not particularly limited, but the reaction is usually carried out under cooling or heating.
- the target compound (I c) or a salt thereof can be obtained by isolating the compound (I b) or a salt thereof obtained by the production method 3 or without isolating it, and subjecting it to an alkynolelation reaction.
- This reaction can be performed by a combination of an aldehyde and a reducing agent or a combination of an alkyl halide and a base.
- Preferred reducing agents include metal water compounds (for example, sodium borohydride, sodium cyanoborohydride, potassium borohydride, bis (2-methoxetoxy) aluminum hydride, etc.), or hydrogen, formic acid or ammonium formate.
- palladium catalysts eg, palladium recharge, palladium hydroxide, palladium black, etc.).
- Preferred bases include inorganic bases (eg, sodium hydrogen carbonate, lium carbonate, etc.) or organic bases (eg, pyridine, triethylamine, etc.). These reactions are usually carried out in a conventional solvent which does not adversely affect the reaction.
- the reaction using a combination of an aldehyde and a reducing agent can be carried out according to the method described in Production Example 23 or Example 8 described later.
- reaction using a combination of a compound having two aldehydes and a reducing agent can be performed according to the method described in Example 31 described later.
- the target compound (Id) or a salt thereof can be produced by subjecting the compound (lb) or a salt thereof obtained by the production method 3 to a cyclic alkylation reaction, with or without isolation. It can.
- This reaction can be performed by a combination of a compound having two aldehyde groups in the molecule and a reducing agent, or a combination of a compound having two halogen groups and a base.
- the target compound (Ie) or a salt thereof is to be subjected to a diazotization reaction followed by a hydroxylation reaction by diazolysis without isolation or isolation of the compound (lb) or a salt thereof obtained by the production method 3.
- a diazotization reaction followed by a hydroxylation reaction by diazolysis without isolation or isolation of the compound (lb) or a salt thereof obtained by the production method 3.
- compound (Ib) or a salt thereof is reacted with sodium nitrite in the presence of an inorganic or organic acid, and the diazonium salt formed is decomposed in water or an organic acid from room temperature to heating. Then, by hydrolysis, the compound (lb) or a salt thereof is obtained.
- Compound (Ie) or a salt thereof can be produced by converting the amino group of the compound into a hydroxyl group.
- Preferred inorganic acids include sulfuric acid, hydrochloric acid, borofluoric acid and the like, and preferred organic acids include acetic acid, trifluoroacetic acid and the like.
- the target compound (If) or a salt thereof can be produced by subjecting the compound (Ie) or a salt thereof obtained by the production method 6 to an alkylation reaction.
- This reaction can be produced by a combination of an alkyl halide and a base.
- Preferred bases include inorganic bases (eg, sodium bicarbonate, carbonated carbonate, etc.) and organic bases (eg, pyridine, triethylamine, etc.).
- the compounds of the present invention or salts thereof have excellent parasiticidal activity as animal and human anthelmintics. It is especially effective against the following nematodes that infect livestock, poultry and pets such as pigs, sheep, goats, cattle, horses, dogs, cats, and chickens. ,
- Tricholongis genus Tricho s trongylus
- Ostertergear genus Tricho rtagia
- Nematodinoles Nematodinoles (Nema tod i.ru s),
- Triconema (Tri chon ema)
- Heterakis He ter ak is
- Toxocara Toxocara
- Ancylostoma (Ancystoma)
- Nematodirus Certain species of the genus Nematodirus, Kupuria and Esophagostomus attack the intestinal tract, whereas only Hemonx and Osterta-Gia parasitize the stomach, and Dictyochaurus parasites It is found in the lung, but is also active.
- parasites of the family Filariidae and Setarii dae are found in other organs such as the viscera and vascular, subcutaneous and lymphatic tissues. Also show activity. -It is also useful against parasites that infect humans, and the most parasites in the human digestive tract are:
- Ankystoma (Ancy 1 os toma),
- Necator Necator
- Liver worms of the genus Filariae include the genus Wuchereria, the genus Brugia, the genus Onchocerca, the genus Locoa (Loa), and the nematode (Drac) It is also active against the genus Dracun 1us of Uncu li da e), the genus Strongyroides and the genus Trichinella in the special extraintestinal parasite of the intestinal parasite.
- Example 1 Compounds shown in Example 1, Example 3, Example 4, Example 5, Example 10, Example 17, Example 17, Example 23, Example 24, Example 25 and Example 29
- the rats used were Wister rats (body weight: 120 g – 130 g, 6-week-old female) and were infected subcutaneously with approximately 3000 infected larvae per rat.
- the test compound is prepared by dissolving 5 mg of the test compound in 0.25 ml of dimethyl sulfoxide, adding a 0.5% aqueous solution of methylcellulose, and adding 100, 10, 5, 2.5, 1.25, 1.0, 0.63, 0.32 mg. The amount of the solution was adjusted to be a dosage of / kg and used.
- the test compound On days 7, 8, and 9 after infection, the test compound was orally administered at the above concentration, and on the 11th day, the test rat was dissected and the number of worms in the small intestine was measured.
- the anthelmintic rate was calculated from the percentage of the number of non-medicated rat (control) worms.
- the anthelmintic rate was calculated in the same manner as in Test Example 1 except that subcutaneous administration instead of oral administration was performed in Test Example 1. Table 2 shows the results.
- Two 8-week-old gerbils in one group were infected with 5,000 larvae of an infected larva of Strangoyloides venezuelensis (Strong ylodeidsvenezuelensis) per animal.
- the test compound suspended on day 10 after infection was orally administered once at each set dosage.
- the effect was determined based on the number of eggs in the feces and the insects in the intestinal tract.
- the number of eggs was measured by the 0-ring method, and the number of eggs in 1 g of feces (EPG) was determined before, on the day of, and on days 1, 2, 3, and 4 after dosing.
- the number of worms was determined by dissecting gerbils on the fourth day after the administration (day 14 of infection). In this measurement method, parasites in the small intestine were emigrated for 1 ⁇ into physiological saline, and the number of parasites was determined as the number of parasites.
- Table 3 shows the results (average value of each group).
- Example-1 2.5 mg ⁇ kg Example-3 1.25 mg 1 kg Example-4 2.5 mg / kg Example-5 0.63 mg / kg Example-10 2.5 mg / kg Example-17 2.5 mg 1 kg Example -235 mg / kg Example-245 mg / kg Example-255 mg / kg Example-295 mg / kg Table-2
- the compound of the present invention When used as an anthelmintic in animals and humans, it can be administered orally as a liquid beverage.
- the beverage may be a solution, suspension or dispersion in a suitable non-toxic solvent or water with suspending and wetting agents or other excipients such as bentonite.
- suspending and wetting agents or other excipients such as bentonite.
- Beverage formulations generally contain from about 0.01 to 0.5% by weight of active compound, preferably from 0.01 to 0.1% by weight. If oral administration in a dry solid unit dosage form is desired, capsules, pills or locks containing the desired amount of the active compound are employed.
- These forms of use consist of homogeneous incorporation of the active ingredient with suitable finely divided diluents, fillers, disintegrants and / or binders, such as starch, lactose, talc, magnesium stearate, vegetable rubber, and the like. It is manufactured by Such unit dosage regimens may vary depending on the type of host animal being treated and the type of parasite. The weight and content of the anthelmintic can vary widely depending on the host and body weight.
- the final feed When administered via animal feed, it may be dispersed homogeneously in the feed, used as a top dressing or in the form of pellets. In general, the final feed contains 0.0001-2% of the active compound in order to achieve the desired antifeedant effect.
- a liquid carrier vehicle can be parenterally administered to animals intranasally, intramuscularly, intratracheally or subcutaneously.
- the active compound is mixed with a suitable vegetable oil, such as peanut oil or cottonseed oil.
- suitable vegetable oil such as peanut oil or cottonseed oil.
- Such formulations generally contain from 0.05 to 50% by weight of active compound.
- a suitable carrier such as dimethyl sulfoxide or a hydrocarbon solvent.
- This formulation is applied directly to the external surface of the animal by spraying or direct pouring.
- the optimal amount of active compound used to achieve a g # result depends on the type of animal being treated and the type of parasite infection, but generally ranges from about 0.01 to 1 mg / kg of animal body weight. Can be obtained by orally administering 0.5 to 50.0 mg. Such usage is a one-time or divided usage; It is given over relatively long intervals, such as ⁇ 5 days.
- Boc-Tyr (Me) -OH (5.1 g) was dissolved in 4N-hydrochloric acid / dioxane (87.5 ml), and the mixture was stirred under ice-cooling for 2 hours. After dioxane was distilled off under reduced pressure, the residue was dissolved in a 6 N aqueous hydrochloric acid solution (45 ml), and sodium nitrite (1.9 g) was added little by little. After stirring for 4 hours as it was, the reaction solution was extracted with ether (100 ml X3). The ether layer was washed with a saturated saline solution, washed with calcium chloride, and the solvent was distilled off under reduced pressure.
- the reaction solution was poured into water (150 ml), extracted with ether (100 ml ⁇ 3), washed with saturated saline, and dried over anhydrous magnesium sulfate.
- the solvent was distilled off under reduced pressure, and the obtained crude product was purified by silica gel chromatography, and eluted with a mixture of ethyl acetate and hexane (1: 8 v / v).
- the solvent of the eluted fraction containing the desired product was distilled off to obtain Boc-MeLeu-D-p-MeOPhLac-OBz1 (1.59 g).
- Bo c-MeLe uDp-MeOPhLa c-OB z 1 (1.36 g) in methanol (15 ml)
- 10% palladium on carbon 0.4 g
- 45 g Hydrogenation was performed for minutes. Remove the catalyst and remove the solvent
- Bo c—MeLeu—D—p—MeOPhLa c—OH (1.08 g) was obtained.
- NMR (CDC 1 3, ⁇ : . 0. 89- 0. 95 (m, 6 H), 1. 4 (s, 9H), 1. 44-1 79 (m, 3 H), 2.
- Boc-MeLeu-D-Lac-OBz 1 (1.04 g) was dissolved in 4N-hydrochloric acid-dioxane (12.5 ml), and the mixture was stirred under ice cooling for 3 hours. After the solvent was distilled off under reduced pressure, azeotropic distillation was performed twice with toluene (10 ml) to obtain H—MeLeu—D—Lac—OBz1 ⁇ HC1 (1).
- the product obtained by evaporating the solvent under reduced pressure was purified by silica gel chromatography, and eluted with a mixture of ethyl acetate-hexane (1: 3 v / v).
- the solvent of the eluted fraction containing the desired product was distilled off to obtain Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OBz1 (1.59 g).
- Bo c-MeL eu-D-p-MeOPhL ac-OH Instead of Boc-MeLeu-D-p-MeOPhLa c-Me Leu-D-Lac-OH (0.67 g) — Me Le u— D— La c— OB 2 I ⁇ HC 1 instead of H-Me Leu -D-p -Me OP h L ac -Me L eu -D-L ac – OB z 1 ⁇ HC 1 (0.74 g), except that B oc — Me L eu— D— p— Me OP h L ac— M e L eu— D— L ac— Me L e uDp-Me 0 P h L ac—Me Leu— D— La c— OB z 1 (0 94g).
- Boc-MeLeuDp-MeOPhLac-OBz1 Instead of Boc-MeLeu—D—p—MeOPhLac—MeLeu—D—Lac-MeLeuDp-MeOPhLac-Me Except that Leu—D— La c— OB z 1 (0.92 g) was used, the procedure was the same as in Production Example 3, so that Bo c— Me Leu— D— p— Me OP hL ac— Me L eu— D— Lac—MeLeu—D—p—MeOPhLa c—M eLeu—D—La c—OH (0.89 g) was obtained. NMR (CDC 1 3,:. . 0. 79 - 0. 99 (m, 24 H), 1. 10-1 80 (m, 27 H), 2. 65-3 10 (m, 16 H), 3 .
- the crude product obtained by concentration under reduced pressure was purified by silica gel chromatography and eluted with a mixture of ethyl acetate'hexane (1: 3, V / V).
- the solvent of the eluted fraction containing the desired product was distilled off to obtain Boc-MeLeu-D-Man-OPac (3 g).
- Boc-MeLeuD-Man-OH (2.22 g) instead of Boc-MeLeuDp-MeOPhLac-OH, H—MeLeu—D—Lac-OB Boc-MeLe uD-Man in the same manner as in Production Example 5 except that H—Me Le eu—DL ac—OT ce ⁇ HC 1 (2.4 g) was used instead of zl-HCl. -MeLe uD-La c-OTce (3.33 g) was obtained.
- Bo c— Me Le u— D— Man— Me Leu-D-Lac-OT ce H-MeLeu-D-Man-MeLeu-D-Lac-OTceHC1 (1.3 g) was prepared in the same manner as in Production Example 7 except that 1.5 g) was used. Obtained.
- Boc-MeLeu-D-p-MeOPLac-OH Boc—MeLeu—D—Man-MeLeu—D—Lac—OH
- Boc-MeLeu-D-Man-OPac Boc-MeLeu—D—Man—MeLeu—D—Lac—MeLeu—D—
- the ethyl ethyl drench layer was washed with saturated saline, dried over anhydrous sodium sulfate, the solvent was distilled off, and the product obtained was purified by silica gel column chromatography. (1 V / V). The solvent on the elution surface containing the desired product was distilled off under reduced pressure to obtain Boc-MeLeu-D-p-MenNPhLac-OBz1 (1.69 g).
- the crude product obtained was purified by silica gel column chromatography, and hexane, ethyl acetate, ethanol (60: 35: 5 V / V).
- the solvent of the eluted fraction containing the desired product is distilled off under reduced pressure and (R) -2-hydroxy-1- (4-morpholinophenyl) benzyl propionate (0.14 g) I got
- H -D - and Mo r PhL a c-OB z 1 is (0. 90 g) except for using Preparation 24 - -M e o NP h L ac - 0 B instead H- D-p of z 1 Similarly, Boc-MeLeu-D-MorPhLac-MeLeu-D-Lac-OBzl (1.36 g) was obtained.
- -OB z 1 (0.74 g) was used.
- OB z 1 (0.73 g) was obtained.
- Negation R (CDC 1 3, ⁇ 1. 95 - 2. 05 (m, 4H), 2, 61 (d, 1 H), 2. 90 (dd, 1H), 3. 03 (dd, 1 H), 3.2—3.3 (m, 4H), 4.43 (ddd, 1H), 5.18 (s, 2H), 6.45 (d, 2H), 6.99 (d, 2H) ), 7.3-7. 4 (m, 5H)
- HDp -Me 2 NP hLac -OBzI B-Oc-Me in the same manner as in Production Example 24 except that H-D-p-PyrPhLac-OBz1 (1.34 g) was used in place of I. L eu—D—p—P yr Ph L ac—OB z 1 (1.79 g) was obtained.
- Boc—MeLeu—D—p—Me 2 NPhLac—OBz 1 In the same manner as in Preparation Example 25 except that Boc—MeLeu—D—p—PyrPhLac—OBzl (1.78 g) was used instead of OBz1. B oc-MeLeu-Dp-PyrPhLa c- OH (1.44 g) was obtained.
- Boc-MeLeu-D-p-PipPhLac-OH (1.38 g) was used instead of Boc-MeLeu-D-MeNPhLac-OH
- Boc—MeLeu—D—p—PipPhLac—MeLeu-D-Lac-OBz1 (2.01 g) was obtained.
- D-La c-OB zl (1.06 g) was obtained.
- B oc-MeLeu-Dp-MEPhLa c-OH (1.29 g) was used in place of B oc- Me LeuD- -MEPL ac -Me Leu -DLac-OBz1 (1.87 g) was obtained.
- B o c-Me Le e uDp-MEPhL a c-Me Le eu -DL ac -OB z 1 HC-H-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-OBz1 0.86 g) were obtained.
- Image R (CDC 1 3, 5) : 0. 79 - 1. 03 (m, 12 H), 1. 21 - 2. 18 (m, 9H), 2. 56 - 2. 72 (m, 3 H) , 2.83-2.99 '(m, 3H), 2.99-3.12 (m, 2H), 3.45 (s, 3H), 3.63-3.8 (m, 3H) 3H), 4.03-4.17 (m, 2H), 5.03-5.
- B oc -Me L e uD- -Me 2 NPhLa c- OB z 1 instead the B oc -Me Leu- D- p- MEPhLa c- MeLeu- D- La c-Me Leu -Dp -MEP L a c- Boc-MeLeu-Dp-MEPhLac—MeLeu—D—In the same manner as in Production Example 25 except that MeLeu-D-Lac-OBz1 (1.22 g) was used. Lac—MeLeu—D—p—MEPhLa c -MeLeu-D-Lac-OH (1.03 g) was obtained.
- Toximethyl chloride (0.85 ml) was added, and the mixture was stirred at room temperature for 18 hours. After dichloromethane was distilled off under reduced pressure, water was added, extracted with ethyl acetate, and dried over magnesium sulfate. After evaporating the solvent under reduced pressure, the obtained product was purified by silica gel column chromatography, and eluted with a mixed solution of hexane and ethyl acetate (6: 1 V / V).
- n-tetrabutylammonium was added to a solution of (R) -l-t-butyl-dimethyl-dimethyl-2-methoxymethoxy-3- (2-methoxyphenyl) propane (2.2 g) in tetrahydrofuran.
- a solution of mufluoride in tetrahydrofuran (Clmo 1 / ⁇ , 6.46 ml) was added, and the mixture was stirred for 2 hours. After distilling off tetrahydrofuran, water was added, extracted with ethyl acetate, and dried over magnesium sulfate.
- the crude product obtained after evaporating the solvent under reduced pressure was purified by silica gel column chromatography, and eluted with a mixture of hexane and ethyl acetate (3: 1 V / V).
- the solvent of the eluted fraction containing the desired product was distilled off under reduced pressure to obtain benzyl (R) -2-hydroxy-3- (2-methoxyphenyl) propionate (1.02 g).
- B oc -Me Leu-Dp-Me 0 NP L ac-OH B oc was prepared in the same manner as in Production Example 26 except that B oc—MeLeu-Do-MeOPhLa c-OH (1.5 g) was used instead of B oc -MeLeuDo-MeOPhLac-MeLeu-D-Lac-OBzl (2.09 g) was obtained.
- Negation R (CDC 1 3, ⁇ ) :.. 1. 9 3 (t, 1H), 2. 06 (d, 1H), 2. 67-2 82 (m, 2 H), 3. 47-3 79 (m, 2H), 3.81 (s, 3H), 3.90-4. 02 (m, 1H), 6.77—6.84 (m, 3H), 7.20- 7.28 (m, 1 H)
- HD-p-Me 9 NPL ac—OB z 1 instead of H—D—m—MeOPhLa c-OB z 1 (0.6 g), use the same procedure as in Production Example 24, except that Bo c—MeLe u—D—m—MeOPhLa c—OB z 1 (1.06 g) was obtained.
- Bo c-MeLeu-Dp-Me 2 NPhLa c-OB z 1 In place of Bo c one MeL eu— D— m— MeOPhLa c— Me Le uDL ac-OB z 1 (0.64 g)
- Boc-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OH (0.6 g) was obtained.
- NMR (CDC 1 3, ⁇ : . 0. 80-0 98 (m, 12 H), 1. 10- 1 ⁇ 75 (m, 18 H), 2. 73 - 3. 22 (m, 8 H), 3.78 (s, 3H), 4.60-5, 85 (m, 4H), 6.75-6.85 (m, 3H), 7.18-7.25 (m, 1H )
- Boc-MeLeu-Dp-MegNPhLac-MeLeuD-Lac-OB Instead of OBzl, Boc—MeLeu—D—m—MeOPhLac—MeLeu— HC 1 H-MeLeu-Dm-MeOPhLac-MeLeu-D-Lac in the same manner as in Production Example 28 except that D— La c— OB zl (0.61) was used. — Obtained OB zl (0.6 g).
- B oc -Me L e uDp-Me o NPhL a c-0B z Instead of 1, B oc — M e L eu— D— m— M e OP h L ac — M e L eu— D— L ac — MeL eu—D—m—Me OP hL ac—Me L eu—D—L ac—OB z 1.
- Boc-MeLe uDp-Me NPhLa c-OB z 1 Boc-MeLe uD-3, 4-DMOPhL ac-OB z 1 (0.34 g)
- Boc—MeLeu—D—3 4-DMOPhLac-OH (0.3 g) was obtained.
- B oc -M eL e uD-3 4 -DMOPhL ac -Me Le uDL ac-Me Le eu -D- 3
- Boc-MeLeuDp-MegNPhLac-OBz1 instead of Boc-MeLeu—D—2,4-DMOPhLac-MeLeuDLac-OBz1 (1.1 g ), Except that B oc — Me L eu—D—2,4-DMO Ph h Ac—Me L eu—DL ac—OH (1) was obtained.
- B oc -Me Le uDp-Me n NPhLa c-OB z 1 Instead of B oc -Me Le eu—D—2,4—DMOPhL ac—Me Le u—D—L ac—Me Le uD-2 , 4— DMOP hL ac—Me L eu— D—L ac— OB zl (1.45 g), except that B oc—Me L eu— D-2, 4-DMOP hLac—MeLeu—D—Lac—MeLeu-D-2, 4-DMOP hLac—MeLeu—D—Lac—OH (1.49 g) was obtained.
- Boc—M in the same manner as in Production Example 24 except that H—D—3, 4—MODPhLa c-OB z 1 (0.5 g) was used instead of HDp-Me 2 NP hL ac-OB z 1. e Leu-D—3,4-MOD PhLac-OB z 1 (0.74 g) was obtained.
- Boc-MeLeuDp-MeoNPhLAc-OH was replaced by Boc-MeLeu-D-3,4-MODPhLac-OH (0.63 g).
- Bo c—Me Le u—D—3,4-MODPhL ac—MeLe u—D—La c—OB zl (0.85 g) was obtained.
- Boc-MeLeuDp-MegNPhLac-OBz1 Instead of Boc-MeLeu—D—3,4—MODPhLac—MeLeu—D—Lac—OBzl (0.42 Boc—MeLeu—D—3,4-MODPhLac-MeLeuDLac-OH (0.39 g) was obtained in the same manner as in Production Example 25 except that g) was used.
- B oc -Me L eu-Dp-Me 9 NPhLa c-0Bz instead of 1, B oc -Me L e uD- 3, 4— MODPhL ac— MeL eu-D-L ac-Me Le uD-3, 4 — MODP hL ac— Me L eu— D— L ac— OB zl (0.59 g), except that B oc— Me Le uD- 3, 4— MODP hL ac— Me L eu— D— L ac— MeL eu-D-3, 4 -MOD P hLa c— MeLe u— D— La c— OH
- N- (t-butoxycarbonyl) -1,3-nitro-l-tyrosine (6.49 g) in dimethylformamide (50 ml) was added potassium carbonate (1.05 g), and methyl iodide (3. 7 ml) and stirred at room temperature for 15 hours.
- Water (500 ml) was added to the reaction solution, and extracted with ethyl acetate (100 ml ⁇ 3). The ethyl acetate layer was washed with brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Hexane and ether were added to the residue for crystallization to give N- (t-butoxycarbonyl) -10-methyl-3-nitro-l-L-tyrosine methyl ester (6.76 g).
- Cesium carbonate (6.5 g) was added to a methanol solution (50 ml) containing acetic acid (2, 3 ml), and the mixture was stirred at room temperature for 30 minutes. The solvent was distilled off to obtain cesium acetate. Cesium acid was added to a solution of (S) -2-chloro-3- (4-methoxy-3-nitrophenyl) ethyl propionate (4.51 g) in dimethylformamide and stirred for 4 hours. Water (200 ml) was added, and the mixture was extracted with ether (10 Om 1 ⁇ 1, 50 ml ⁇ 2).
- the purified product was purified by silica gel column chromatography,
- H—D—3MA—4MOPhL ac-OB z 1 (0.90 g)
- B was prepared in the same manner as in Production Example 24.
- 4 DMAP hL ac—Me L eu— D—L ac—OB zl (0.34 g)
- B oc—Me Le uD- 3 4 -DMAP L ac -Me Le uDL ac-MeLe uD-3
- Benzene (20 ml), benzyl alcohol in the residue (1.32 ml) and p-toluenesulfonic acid monohydrate (0.33 g) were added, and the mixture was heated under reflux for 1 hour using a Gene-Stark apparatus.
- OB zl (0.61 g) was used.
- Boc-MeLeu-D-p-MegNPhLac-MeLeu-DLac-OBz 1 Instead of Boc-MeLeuDp-FPhL ac-MeLeu-DLac HC 1H-MeL e uDp -FPhL ac -Me Le uDL ac -OB z 1 (0.85 g) except that -OB z 1 (0.89 g) was used. g) was obtained.
- B oc -Me L e uDp -Me gNPhL a c-OB z 1 Instead of B oc —Me L eu—D—p—Me OPhL ac—Me L eu—G 1 yco 1—Me L eu -Dp -Me OPhL ac -Me Leu-Glyco 1 -OB z 1 (0.58 g) Except for using 0.58 g of Boc—MeLeu—D——Me0PhLac—Me L eu—G 1 yco 1—Me L eu—D—p—MeOPhLac—MeLeu—Glycol—OH (0.55 g) was obtained. -IR (KB r): 1742, 1664 cm— 1
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1993631414 DE122005000058I1 (de) | 1992-03-17 | 1993-03-08 | Depsipeptide, Herstellung und Anwendung |
DE69331414T DE69331414T2 (de) | 1992-03-17 | 1993-03-08 | Depsipeptide, herstellung und anwendung |
EP93905622A EP0634408B1 (en) | 1992-03-17 | 1993-03-08 | Depsipeptide derivative, production thereof and use thereof |
AU36483/93A AU669883B2 (en) | 1992-03-17 | 1993-03-08 | Depsipeptide derivative, production thereof and use thereof |
CA002132199A CA2132199C (en) | 1992-03-17 | 1993-03-08 | Depsipeptide derivative, production thereof and use thereof |
DK93905622T DK0634408T3 (da) | 1992-03-17 | 1993-03-08 | Depsipeptidderivater, fremstilling og anvendelse deraf |
AT93905622T ATE211466T1 (de) | 1992-03-17 | 1993-03-08 | Depsipeptide, herstellung und anwendung |
US08/295,782 US5514773A (en) | 1992-01-15 | 1993-03-08 | Depsipeptide derivatives, production thereof and use thereof |
HK98103723A HK1004481A1 (en) | 1992-03-17 | 1998-05-01 | Depsipeptide derivative, production thereof and use thereof |
LU91210C LU91210I2 (fr) | 1992-03-17 | 2005-12-21 | Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER) |
NL300215C NL300215I1 (nl) | 1992-03-17 | 2006-01-13 | Depsipeptide-derivaat, productie daarvan en toepassing daarvan. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4/92070 | 1992-03-17 | ||
JP9207092 | 1992-03-17 | ||
JP4/305093 | 1992-10-15 | ||
JP30509392 | 1992-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993019053A1 true WO1993019053A1 (fr) | 1993-09-30 |
Family
ID=26433555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/000286 WO1993019053A1 (fr) | 1992-01-15 | 1993-03-08 | Derive de depsipeptide, production et utilisation |
Country Status (16)
Country | Link |
---|---|
US (1) | US5514773A (ja) |
EP (1) | EP0634408B1 (ja) |
JP (1) | JP2874342B2 (ja) |
CN (1) | CN1039331C (ja) |
AT (1) | ATE211466T1 (ja) |
AU (1) | AU669883B2 (ja) |
CA (1) | CA2132199C (ja) |
DE (2) | DE122005000058I1 (ja) |
DK (1) | DK0634408T3 (ja) |
ES (1) | ES2166359T3 (ja) |
HK (1) | HK1004481A1 (ja) |
LU (1) | LU91210I2 (ja) |
NL (1) | NL300215I1 (ja) |
NZ (1) | NZ249588A (ja) |
PT (1) | PT634408E (ja) |
WO (1) | WO1993019053A1 (ja) |
Cited By (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007272A1 (en) * | 1993-09-06 | 1995-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Cyclodepsipeptide compound |
EP0685469A4 (en) * | 1993-02-19 | 1996-04-03 | Meiji Seika Kaisha | DERIVATIVE OF PF 1022 USED AS A CYCLIC DEPSIPEPTIDE. |
WO1996038165A2 (de) * | 1995-06-02 | 1996-12-05 | Bayer Aktiengesellschaft | Endoparasitizide mittel |
WO1997002256A1 (fr) * | 1995-06-30 | 1997-01-23 | Fujisawa Pharmaceutical Co., Ltd. | Derive depsipeptidique, son procede de production et son nouvel intermediaire |
WO1997009331A1 (en) * | 1995-09-07 | 1997-03-13 | Pharmacia & Upjohn Company | Cycloanthelmintic inhibitors |
WO1997011064A1 (fr) * | 1995-09-22 | 1997-03-27 | Meiji Seika Kaisha, Ltd. | Nouveaux derives depsipeptides cycliques de pf1022 |
WO1998037088A1 (en) * | 1997-02-19 | 1998-08-27 | Meiji Seika Kaisha Ltd. | Derivatives of cyclodepsipeptide, pf1022 substance |
US6136838A (en) * | 1998-03-19 | 2000-10-24 | Merck & Co., Inc. | Sulfurpentafluorophenylpyrazoles for controlling ectoparasitic infestations |
US6221894B1 (en) | 1995-03-20 | 2001-04-24 | Merck & Co., Inc. | Nodulisporic acid derivatives |
US6346603B1 (en) * | 1997-11-10 | 2002-02-12 | Fujisawa Pharmaceutical Co., Ltd. | Crystal of depsipeptide derivative and process for producing the same |
JP2003518019A (ja) * | 1999-12-22 | 2003-06-03 | バイエル アクチェンゲゼルシャフト | 有害生物抑制剤/pf1022−221 |
JP2003523397A (ja) * | 2000-02-22 | 2003-08-05 | バイエル アクチェンゲゼルシャフト | 殺内部寄生虫剤 |
JP2007314580A (ja) * | 1994-01-11 | 2007-12-06 | Bayer Ag | 内寄生性生物防除剤である組成物 |
DE102008022520A1 (de) | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
DE102008030764A1 (de) | 2008-06-28 | 2009-12-31 | Bayer Animal Health Gmbh | Kombination von Amidin-Derivaten mit cyclischen Depsipeptiden |
DE102008031283A1 (de) | 2008-07-02 | 2010-01-07 | Bayer Schering Pharma Aktiengesellschaft | Neue Bekämpfungsmöglichkeit von durch Trichomonadida hervorgerufenen Krankheiten |
DE102008031284A1 (de) | 2008-07-02 | 2010-01-07 | Bayer Schering Pharma Aktiengesellschaft | Neue Bekämpfungsmöglichkeit der Giardiose |
US7687533B2 (en) | 2004-03-18 | 2010-03-30 | Pfizer Inc. | N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides |
WO2010102762A1 (de) | 2009-03-10 | 2010-09-16 | Bayer Animal Health Gmbh | Zubereitung auf ölbasis enthaltend anti-protozoische triazine und anthelmintische cyclodepsipeptide |
JP2010222361A (ja) * | 1995-08-11 | 2010-10-07 | Bayer Animal Health Gmbh | ジデプシペプチドおよびその殺内部寄生虫薬としての使用 |
WO2011067272A1 (en) | 2009-12-01 | 2011-06-09 | Syngenta Participations Ag | Insecticidal compounds based on isoxazoline derivatives |
WO2011101402A1 (en) | 2010-02-17 | 2011-08-25 | Syngenta Participations Ag | Isoxazoline derivatives as insecticides |
WO2011101229A1 (en) | 2010-02-22 | 2011-08-25 | Syngenta Participations Ag | Dihydrofuran derivatives as insecticidal compounds |
WO2011104089A1 (en) | 2010-02-25 | 2011-09-01 | Syngenta Participations Ag | Process for the preparation of isoxazoline derivatives |
WO2012028556A1 (en) | 2010-08-31 | 2012-03-08 | Bayer Animal Health Gmbh | Macrocyclic lactones and their use and their combinations with other active substances |
WO2012045700A1 (en) | 2010-10-05 | 2012-04-12 | Syngenta Participations Ag | Insecticidal pyrrolidin-yl-aryl-carboxamides |
WO2012049327A2 (en) | 2010-10-15 | 2012-04-19 | Syngenta Participations Ag | Pesticidal mixtures |
WO2012069366A1 (en) | 2010-11-23 | 2012-05-31 | Syngenta Participations Ag | Insecticidal compounds |
WO2012080376A1 (en) | 2010-12-17 | 2012-06-21 | Syngenta Participations Ag | Insecticidal compounds |
DE102010064245A1 (de) | 2010-12-28 | 2012-06-28 | Bayer Animal Health Gmbh | Makrocylischen Lactone und deren Verwendung und deren Kombinationen mit anderen Wirkstoffen |
WO2012107434A1 (en) | 2011-02-09 | 2012-08-16 | Syngenta Participations Ag | Insecticidal compounds |
WO2012126881A1 (en) | 2011-03-22 | 2012-09-27 | Syngenta Participations Ag | Insecticidal compounds |
WO2012156400A1 (en) | 2011-05-18 | 2012-11-22 | Syngenta Participations Ag | Insecticidal compounds based on arylthioacetamide derivatives |
WO2012163959A1 (en) | 2011-05-31 | 2012-12-06 | Syngenta Participations Ag | Insecticidal compounds |
WO2012163948A1 (en) | 2011-05-31 | 2012-12-06 | Syngenta Participations Ag | Pesticidal mixtures including isoxazoline derivatives |
WO2012175474A1 (en) | 2011-06-20 | 2012-12-27 | Syngenta Participations Ag | 1,2,3 triazole pesticides |
WO2013026695A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Isoxazoline derivatives as insecticidal compounds |
WO2013026933A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Isoxazoline derivatives as insecticidal compounds |
WO2013026930A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Process for the preparation of thietane derivatives |
WO2013026931A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Isoxazoline derivatives as insecticidal compounds |
WO2013026724A1 (en) | 2011-08-22 | 2013-02-28 | Syngenta Participations Ag | Dihydrofuran derivatives as insecticidal compounds |
WO2013026726A1 (en) | 2011-08-22 | 2013-02-28 | Syngenta Participations Ag | Dihydrofuran derivatives as insecticidal compounds |
WO2013026929A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Dihydropyrrole derivatives as insecticidal compounds |
WO2013037626A1 (en) | 2011-09-13 | 2013-03-21 | Syngenta Participations Ag | Isothiazoline derivatives as insecticidal compounds |
WO2013050261A1 (en) | 2011-10-03 | 2013-04-11 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
WO2013050302A1 (en) | 2011-10-03 | 2013-04-11 | Syngenta Participations Ag | Isoxazoline derivatives as insecticidal compounds |
WO2013057624A1 (en) | 2011-10-19 | 2013-04-25 | Ah Usa 42 Llc | Use of aminoacetonitrile derivatives against endoparasites |
WO2013092558A1 (de) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Zubereitungen enthaltend amorphes emodepsid |
KR101280511B1 (ko) * | 2004-11-16 | 2013-07-01 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 체내기생충의 수직 감염 예방 |
WO2013135674A1 (en) | 2012-03-12 | 2013-09-19 | Syngenta Participations Ag | Insecticidal 2-aryl-acetamide compounds |
WO2013187480A1 (ja) | 2012-06-13 | 2013-12-19 | Meiji Seikaファルマ株式会社 | 新規環状デプシペプチド誘導体およびそれを含んでなる有害生物防除剤 |
WO2014001121A1 (en) | 2012-06-25 | 2014-01-03 | Syngenta Participations Ag | Isothiazole derivatives as insecticidal compounds |
WO2014001120A1 (en) | 2012-06-25 | 2014-01-03 | Syngenta Participations Ag | Isothiazole derivatives as insecticidal compounds |
WO2014067838A1 (en) | 2012-10-31 | 2014-05-08 | Syngenta Participations Ag | Insecticidal compounds |
WO2014079935A1 (en) | 2012-11-21 | 2014-05-30 | Syngenta Participations Ag | Insecticidal compounds based on arylthioacetamide derivatives |
WO2014161849A1 (en) | 2013-04-02 | 2014-10-09 | Syngenta Participations Ag | Insecticidal compounds |
WO2014161848A1 (en) | 2013-04-02 | 2014-10-09 | Syngenta Participations Ag | Insecticidal compounds |
WO2015007451A1 (en) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2016087593A1 (en) | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
WO2016155831A1 (en) | 2015-04-02 | 2016-10-06 | Syngenta Participations Ag | Isoxazoline-styrene derivatives as insecticidal compounds |
WO2017055473A1 (en) | 2015-10-02 | 2017-04-06 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017072247A1 (en) | 2015-10-28 | 2017-05-04 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017076982A1 (en) | 2015-11-04 | 2017-05-11 | Syngenta Participations Ag | Microbiocidal anilide derivatives |
WO2017093348A1 (en) | 2015-12-02 | 2017-06-08 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017102006A1 (en) | 2015-12-17 | 2017-06-22 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017157962A1 (en) | 2016-03-15 | 2017-09-21 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017162868A1 (en) | 2016-03-24 | 2017-09-28 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017174158A1 (en) | 2016-04-08 | 2017-10-12 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017178408A1 (en) | 2016-04-15 | 2017-10-19 | Syngenta Participations Ag | Microbiocidal silicon containing aryl derivatives |
WO2017178549A1 (en) | 2016-04-12 | 2017-10-19 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017207362A1 (en) | 2016-05-30 | 2017-12-07 | Syngenta Participations Ag | Microbiocidal thiazole derivatives |
WO2017207757A1 (en) | 2016-06-03 | 2017-12-07 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017220485A1 (en) | 2016-06-21 | 2017-12-28 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018015458A1 (en) | 2016-07-22 | 2018-01-25 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018015449A1 (en) | 2016-07-22 | 2018-01-25 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018015447A1 (en) | 2016-07-22 | 2018-01-25 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018029242A1 (en) | 2016-08-11 | 2018-02-15 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018055135A1 (en) | 2016-09-23 | 2018-03-29 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018055133A1 (en) | 2016-09-23 | 2018-03-29 | Syngenta Participations Ag | Microbiocidal tetrazolone derivatives |
WO2018065414A1 (en) | 2016-10-06 | 2018-04-12 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
JP2018516904A (ja) * | 2015-05-20 | 2018-06-28 | メリアル インコーポレイテッド | 駆虫性デプシペプチド化合物 |
WO2018158365A1 (en) | 2017-03-03 | 2018-09-07 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018162643A1 (en) | 2017-03-10 | 2018-09-13 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018185013A1 (en) | 2017-04-03 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184987A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184984A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184985A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184986A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184982A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018185211A1 (en) | 2017-04-06 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184988A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018206419A1 (en) | 2017-05-12 | 2018-11-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2018219825A1 (en) | 2017-06-02 | 2018-12-06 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2019012011A1 (en) | 2017-07-12 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019011923A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019011926A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019011928A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019012001A1 (en) | 2017-07-12 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019012003A1 (en) | 2017-07-13 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019011929A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019053026A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053010A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053016A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053019A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053024A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053015A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053027A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019068809A1 (en) | 2017-10-05 | 2019-04-11 | Syngenta Participations Ag | MICROBIOCIDE PICOLINAMIDE DERIVATIVES |
WO2019068812A1 (en) | 2017-10-05 | 2019-04-11 | Syngenta Participations Ag | MICROBIOCIDE PICOLINAMIDE DERIVATIVES |
EP3480195A1 (en) | 2017-11-07 | 2019-05-08 | Bayer Animal Health GmbH | Method for the synthesis of cyclic depsipeptides |
WO2019091975A1 (en) | 2017-11-07 | 2019-05-16 | Bayer Animal Health Gmbh | Method for the synthesis of cyclic depsipeptides |
WO2019096709A1 (en) | 2017-11-15 | 2019-05-23 | Syngenta Participations Ag | Microbiocidal picolinamide derivatives |
WO2019097054A1 (en) | 2017-11-20 | 2019-05-23 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2019105933A1 (en) | 2017-11-29 | 2019-06-06 | Syngenta Participations Ag | Microbiocidal thiazole derivatives |
WO2019121394A1 (en) | 2017-12-19 | 2019-06-27 | Syngenta Participations Ag | Polymorphs |
WO2019121149A1 (en) | 2017-12-19 | 2019-06-27 | Syngenta Participations Ag | Microbiocidal picolinamide derivatives |
EP3556744A1 (en) | 2013-12-23 | 2019-10-23 | Syngenta Participations Ag | Insecticidal compounds |
WO2019207062A1 (en) | 2018-04-26 | 2019-10-31 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2019224160A1 (en) | 2018-05-25 | 2019-11-28 | Syngenta Participations Ag | Microbiocidal picolinamide derivatives |
WO2020002331A1 (en) | 2018-06-29 | 2020-01-02 | Syngenta Crop Protection Ag | Microbiocidal oxadiazole derivatives |
WO2020007658A1 (en) | 2018-07-02 | 2020-01-09 | Syngenta Crop Protection Ag | 3-(2-thienyl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as agrochemical fungicides |
WO2020016180A1 (en) | 2018-07-16 | 2020-01-23 | Syngenta Crop Protection Ag | Microbiocidal oxadiazole derivatives |
WO2020025807A1 (en) | 2018-08-03 | 2020-02-06 | Syngenta Crop Protection Ag | Microbiocidal 1,2,5-oxadiazol-3(2h)-one derivatives |
WO2020058207A1 (en) | 2018-09-19 | 2020-03-26 | Syngenta Crop Protection Ag | Microbiocidal quinoline carboxamide derivatives |
WO2020070132A1 (en) | 2018-10-06 | 2020-04-09 | Syngenta Participations Ag | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives |
WO2020070131A1 (en) | 2018-10-06 | 2020-04-09 | Syngenta Participations Ag | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives |
WO2020078732A1 (en) | 2018-10-17 | 2020-04-23 | Syngenta Crop Protection Ag | Microbiocidal oxadiazole derivatives |
WO2020079111A1 (en) | 2018-10-18 | 2020-04-23 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2020109509A1 (en) | 2018-11-30 | 2020-06-04 | Syngenta Participations Ag | Microbiocidal thiazole derivatives |
WO2020109511A1 (en) | 2018-11-30 | 2020-06-04 | Syngenta Crop Protection Ag | Microbiocidal 2-acylamino-thiazole-4-carboxamide derivatives |
EP3683213A1 (en) | 2015-03-27 | 2020-07-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2020165403A1 (en) | 2019-02-15 | 2020-08-20 | Syngenta Crop Protection Ag | Phenyl substituted thiazole derivatives as microbiocidal compounds |
WO2020193618A1 (en) | 2019-03-27 | 2020-10-01 | Syngenta Crop Protection Ag | Microbiocidal thiazole derivatives |
WO2020193387A1 (en) | 2019-03-22 | 2020-10-01 | Syngenta Crop Protection Ag | Fungicidal compounds |
WO2020208095A1 (en) | 2019-04-10 | 2020-10-15 | Syngenta Crop Protection Ag | Microbiocidal picolinamide derivatives |
WO2020239854A1 (en) | 2019-05-29 | 2020-12-03 | Syngenta Crop Protection Ag | Microbiocidal derivatives |
WO2020239856A1 (en) | 2019-05-29 | 2020-12-03 | Syngenta Crop Protection Ag | Microbiocidal derivatives |
WO2020239853A1 (en) | 2019-05-29 | 2020-12-03 | Syngenta Crop Protection Ag | Microbiocidal derivatives |
WO2020239855A1 (en) | 2019-05-29 | 2020-12-03 | Syngenta Crop Protection Ag | Microbiocidal derivatives |
WO2021004968A1 (en) | 2019-07-05 | 2021-01-14 | Syngenta Crop Protection Ag | Microbiocidal picolinamide derivatives |
WO2021009026A1 (en) | 2019-07-12 | 2021-01-21 | Syngenta Crop Protection Ag | Methyl 2-[(4-methoxyimino-tetralin-6-yl]prop-2-enoate derivatives, chromane, isochromane, 6,7,8,9-tetrahydrobenzo[7]annulene, 1h-isobenzofurane and indane analogues thereof, and similar compounds, as agrochemical fungicides |
WO2021028479A1 (en) | 2019-08-14 | 2021-02-18 | Vetoquinol S.A. | Compositions comprising tigolaner for controlling parasites |
WO2021032634A1 (en) | 2019-08-21 | 2021-02-25 | Syngenta Participations Ag | Apparatus and method for reducing dust development in precision drill sowing |
WO2021032633A1 (en) | 2019-08-21 | 2021-02-25 | Syngenta Participations Ag | High precision greenhouse seed and seedling treatment |
WO2021032632A1 (en) | 2019-08-21 | 2021-02-25 | Syngenta Participations Ag | Apparatus and method for converting existing sowing equipment |
WO2021032631A1 (en) | 2019-08-21 | 2021-02-25 | Syngenta Participations Ag | Precision treatment and sowing or planting method and device |
WO2021032630A1 (en) | 2019-08-21 | 2021-02-25 | Syngenta Participations Ag | Sowing device and method for treating seeds during planting |
US10959970B2 (en) | 2009-02-16 | 2021-03-30 | Nogra Pharma Limited | Methods of treating hair related conditions |
US11046641B2 (en) | 2012-02-09 | 2021-06-29 | Nogra Pharma Limited | Methods of treating fibrosis |
WO2021204855A1 (en) | 2020-04-08 | 2021-10-14 | Syngenta Crop Protection Ag | Microbiocidal quinoline dihydropyrrolopyrazine derivatives |
WO2021204822A1 (en) | 2020-04-08 | 2021-10-14 | Syngenta Crop Protection Ag | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives |
WO2021204857A1 (en) | 2020-04-08 | 2021-10-14 | Syngenta Crop Protection Ag | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives |
WO2021219775A1 (en) | 2020-04-30 | 2021-11-04 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2021219780A1 (en) | 2020-05-01 | 2021-11-04 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2021219778A1 (en) | 2020-04-30 | 2021-11-04 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2021224102A1 (en) | 2020-05-05 | 2021-11-11 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2021244952A1 (en) | 2020-06-03 | 2021-12-09 | Syngenta Crop Protection Ag | Microbiocidal derivatives |
WO2022058580A1 (en) | 2020-09-21 | 2022-03-24 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2022207479A1 (en) | 2021-03-27 | 2022-10-06 | Syngenta Crop Protection Ag | Microbiocidal isonicotinic amide derivatives |
WO2022207665A1 (en) | 2021-03-31 | 2022-10-06 | Syngenta Crop Protection Ag | Microbiocidal quinoline/quinoxaline benzothiazine derivatives |
WO2022223376A1 (en) | 2021-04-20 | 2022-10-27 | Syngenta Crop Protection Ag | Microbiocidal quinoline/quinoxaline isoquinoline derivatives |
WO2023012044A1 (en) | 2021-08-02 | 2023-02-09 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2023089049A2 (en) | 2021-11-19 | 2023-05-25 | Syngenta Crop Protection Ag | Microbiocidal isonicotinic amide derivatives |
WO2023094303A1 (en) | 2021-11-25 | 2023-06-01 | Syngenta Crop Protection Ag | Microbiocidal heterobiaryl amide derivatives |
WO2023094304A1 (en) | 2021-11-25 | 2023-06-01 | Syngenta Crop Protection Ag | Microbiocidal heterobiaryl amide derivatives |
WO2023110869A1 (en) | 2021-12-15 | 2023-06-22 | Syngenta Crop Protection Ag | Microbiocidal bicycle heterocyclic derivatives |
WO2023111215A1 (en) | 2021-12-17 | 2023-06-22 | Syngenta Crop Protection Ag | Microbiocidal pyridine-substituted benzothiazine derivatives |
WO2023110871A1 (en) | 2021-12-17 | 2023-06-22 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2023118011A1 (en) | 2021-12-22 | 2023-06-29 | Syngenta Crop Protection Ag | Microbiocidal aza-heterobiaryl derivatives |
WO2023139166A1 (en) | 2022-01-19 | 2023-07-27 | Syngenta Crop Protection Ag | Methods for controlling plant pathogens |
WO2023148206A1 (en) | 2022-02-02 | 2023-08-10 | Syngenta Crop Protection Ag | Microbiocidal n-amide derivatives |
WO2023166067A1 (en) | 2022-03-02 | 2023-09-07 | Syngenta Crop Protection Ag | Microbiocidal pyridazinone amide derivatives |
WO2023247552A1 (en) | 2022-06-21 | 2023-12-28 | Syngenta Crop Protection Ag | Microbiocidal bicyclic heterocyclic carboxamide derivatives |
WO2024018016A1 (en) | 2022-07-21 | 2024-01-25 | Syngenta Crop Protection Ag | Crystalline forms of 1,2,4-oxadiazole fungicides |
US11905232B2 (en) | 2019-02-08 | 2024-02-20 | Nogra Pharma Limited | Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
WO2024068947A1 (en) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2024068655A1 (en) | 2022-09-28 | 2024-04-04 | Syngenta Crop Protection Ag | Fungicidal compositions |
WO2024068656A1 (en) | 2022-09-28 | 2024-04-04 | Syngenta Crop Protection Ag | Fungicidal compositions |
WO2024068950A1 (en) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2024089191A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Microbiocidal heterobicyclic dihydrooxadiazine derivatives |
WO2024100069A1 (en) | 2022-11-08 | 2024-05-16 | Syngenta Crop Protection Ag | Microbiocidal pyridine derivatives |
WO2024100115A1 (en) | 2022-11-09 | 2024-05-16 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2024105104A1 (en) | 2022-11-16 | 2024-05-23 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline derivatives |
WO2024115512A1 (en) | 2022-11-30 | 2024-06-06 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline derivatives |
WO2024115509A1 (en) | 2022-11-29 | 2024-06-06 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline derivatives |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69721055T2 (de) | 1996-10-07 | 2004-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Verfahren zur herstellung von depsipeptiden und zwischenprodukten davon |
AU4624997A (en) * | 1996-10-10 | 1998-05-05 | Bayer Aktiengesellschaft | Nematode proteins, dna sequences coding therefor, their specific antibodies and their use in identifying nematicidal active substances |
DE19713626A1 (de) * | 1997-04-02 | 1998-10-08 | Bayer Ag | Neue Thiodepsipeptide zur Bekämpfung von Endoparasiten und ein einfaches Verfahren zu ihrer Herstellung |
BR9810412A (pt) * | 1997-06-04 | 2000-08-22 | Bayer Ag | Desoxiciclodepsipeptìdios e seu emprego para o combate de endoparasitas |
DE19811559A1 (de) * | 1998-03-17 | 1999-09-23 | Bayer Ag | Cyclooctadepsipeptide |
DE19828043A1 (de) | 1998-06-24 | 1999-12-30 | Bayer Ag | Ektoparasitizide Mittel |
JP4156235B2 (ja) * | 1999-09-29 | 2008-09-24 | 明治製菓株式会社 | 官能基により修飾された二次代謝産物を生産する形質転換体および新規生合成遺伝子 |
DE19962145A1 (de) * | 1999-12-22 | 2001-06-28 | Bayer Ag | Schädlingsbekämpfungsmittel/Depsipeptide |
DE10031044A1 (de) * | 2000-06-26 | 2002-01-03 | Bayer Ag | Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere |
DE10104362A1 (de) * | 2001-02-01 | 2002-08-08 | Bayer Ag | Kristallmodifikation eines cyclischen Depsipeptids mit besserer Wirksamkeit |
WO2003002508A1 (en) * | 2001-06-28 | 2003-01-09 | Dr. Reddy's Research Foundation | Derivatives of para-ethoxy-phenillactic acid |
JP2008520682A (ja) * | 2004-11-17 | 2008-06-19 | ザ ユニヴァーシティー オヴ シカゴ | ヒストンデアセチラーゼ阻害剤およびその使用方法 |
DE102005011779A1 (de) * | 2005-03-11 | 2006-09-14 | Bayer Healthcare Ag | Endoparasitizide Mittel |
WO2008151306A1 (en) * | 2007-06-05 | 2008-12-11 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Synthesis of cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity |
JP6943859B2 (ja) | 2015-12-28 | 2021-10-06 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 駆虫性デプシペプチド化合物 |
CN105613526A (zh) * | 2016-02-24 | 2016-06-01 | 燕素琴 | 一种防治林业害虫杨树天牛的药膏 |
CA3044038A1 (en) | 2016-11-16 | 2018-05-24 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic depsipeptide compounds |
SG11202003832WA (en) | 2017-11-29 | 2020-06-29 | Zoetis Services Llc | Endoparasitic depsipeptides |
EP3790876A1 (en) | 2018-05-10 | 2021-03-17 | Zoetis Services LLC | Endoparasitic depsipeptides |
EP3908330A1 (en) | 2019-01-10 | 2021-11-17 | Zoetis Services LLC | Anthelmintic laboratory animal model for heartworm |
AU2021410052A1 (en) | 2020-12-21 | 2023-08-03 | Boehringer Ingelheim Vetmedica Gmbh | Parasiticidal collar comprising isoxazoline compounds |
CN114195732A (zh) * | 2022-01-04 | 2022-03-18 | 丽珠集团福州福兴医药有限公司 | 一种艾默德斯的单晶型iii及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0335796A (ja) * | 1989-02-07 | 1991-02-15 | Meiji Seika Kaisha Ltd | 環状デプシペプチド物質およびその製造法、ならびにそれを含有する駆虫剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2731245B2 (ja) * | 1989-06-01 | 1998-03-25 | 株式会社デジタル | グラフィックディスプレイ装置 |
DK223690D0 (da) * | 1990-09-17 | 1990-09-17 | Novo Nordisk As | Hidtil ukendte forbindelser |
JPH0570366A (ja) * | 1991-03-08 | 1993-03-23 | Meiji Seika Kaisha Ltd | 薬用組成物 |
DE4317458A1 (de) * | 1992-06-11 | 1993-12-16 | Bayer Ag | Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung |
CN1073560C (zh) * | 1993-02-19 | 2001-10-24 | 明治制果株式会社 | 环缩酚酸肽pf1022衍生物 |
-
1993
- 1993-03-08 AT AT93905622T patent/ATE211466T1/de active
- 1993-03-08 DE DE1993631414 patent/DE122005000058I1/de active Pending
- 1993-03-08 AU AU36483/93A patent/AU669883B2/en not_active Expired
- 1993-03-08 PT PT93905622T patent/PT634408E/pt unknown
- 1993-03-08 US US08/295,782 patent/US5514773A/en not_active Expired - Lifetime
- 1993-03-08 DE DE69331414T patent/DE69331414T2/de not_active Expired - Lifetime
- 1993-03-08 ES ES93905622T patent/ES2166359T3/es not_active Expired - Lifetime
- 1993-03-08 NZ NZ249588A patent/NZ249588A/en not_active IP Right Cessation
- 1993-03-08 CA CA002132199A patent/CA2132199C/en not_active Expired - Lifetime
- 1993-03-08 EP EP93905622A patent/EP0634408B1/en not_active Expired - Lifetime
- 1993-03-08 WO PCT/JP1993/000286 patent/WO1993019053A1/ja active IP Right Grant
- 1993-03-08 DK DK93905622T patent/DK0634408T3/da active
- 1993-03-08 JP JP5516418A patent/JP2874342B2/ja not_active Expired - Lifetime
- 1993-03-16 CN CN93104409A patent/CN1039331C/zh not_active Expired - Lifetime
-
1998
- 1998-05-01 HK HK98103723A patent/HK1004481A1/xx not_active IP Right Cessation
-
2005
- 2005-12-21 LU LU91210C patent/LU91210I2/fr unknown
-
2006
- 2006-01-13 NL NL300215C patent/NL300215I1/nl unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0335796A (ja) * | 1989-02-07 | 1991-02-15 | Meiji Seika Kaisha Ltd | 環状デプシペプチド物質およびその製造法、ならびにそれを含有する駆虫剤 |
Cited By (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0685469A4 (en) * | 1993-02-19 | 1996-04-03 | Meiji Seika Kaisha | DERIVATIVE OF PF 1022 USED AS A CYCLIC DEPSIPEPTIDE. |
WO1995007272A1 (en) * | 1993-09-06 | 1995-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Cyclodepsipeptide compound |
CN1061039C (zh) * | 1993-09-06 | 2001-01-24 | 藤泽药品工业株式会社 | 环状缩酚酸肽化合物或其盐及其制备方法和用途 |
JP2007314580A (ja) * | 1994-01-11 | 2007-12-06 | Bayer Ag | 内寄生性生物防除剤である組成物 |
US6221894B1 (en) | 1995-03-20 | 2001-04-24 | Merck & Co., Inc. | Nodulisporic acid derivatives |
WO1996038165A2 (de) * | 1995-06-02 | 1996-12-05 | Bayer Aktiengesellschaft | Endoparasitizide mittel |
WO1996038165A3 (de) * | 1995-06-02 | 1997-01-09 | Bayer Ag | Endoparasitizide mittel |
WO1997002256A1 (fr) * | 1995-06-30 | 1997-01-23 | Fujisawa Pharmaceutical Co., Ltd. | Derive depsipeptidique, son procede de production et son nouvel intermediaire |
US5856436A (en) * | 1995-06-30 | 1999-01-05 | Fujisawa Pharmaceutical Co., Ltd. | Depsipeptide derivative, process for production thereof, and novel intermediate therefor |
CN1071323C (zh) * | 1995-06-30 | 2001-09-19 | 藤泽药品工业株式会社 | 缩肽衍生物或其盐的制造方法 |
JP2010222361A (ja) * | 1995-08-11 | 2010-10-07 | Bayer Animal Health Gmbh | ジデプシペプチドおよびその殺内部寄生虫薬としての使用 |
WO1997009331A1 (en) * | 1995-09-07 | 1997-03-13 | Pharmacia & Upjohn Company | Cycloanthelmintic inhibitors |
CN1082051C (zh) * | 1995-09-22 | 2002-04-03 | 明治制果株式会社 | 新的环缩肽pf1022物质的衍生物 |
US6329338B1 (en) * | 1995-09-22 | 2001-12-11 | Meiji Seika Kaisha, Ltd. | Derivatives of cyclodepsipeptide PF1022 substance |
WO1997011064A1 (fr) * | 1995-09-22 | 1997-03-27 | Meiji Seika Kaisha, Ltd. | Nouveaux derives depsipeptides cycliques de pf1022 |
WO1998037088A1 (en) * | 1997-02-19 | 1998-08-27 | Meiji Seika Kaisha Ltd. | Derivatives of cyclodepsipeptide, pf1022 substance |
US6346603B1 (en) * | 1997-11-10 | 2002-02-12 | Fujisawa Pharmaceutical Co., Ltd. | Crystal of depsipeptide derivative and process for producing the same |
US6136838A (en) * | 1998-03-19 | 2000-10-24 | Merck & Co., Inc. | Sulfurpentafluorophenylpyrazoles for controlling ectoparasitic infestations |
JP2003518019A (ja) * | 1999-12-22 | 2003-06-03 | バイエル アクチェンゲゼルシャフト | 有害生物抑制剤/pf1022−221 |
JP4801303B2 (ja) * | 1999-12-22 | 2011-10-26 | バイエル アクチェンゲゼルシャフト | 有害生物抑制剤/pf1022−221 |
JP2003523397A (ja) * | 2000-02-22 | 2003-08-05 | バイエル アクチェンゲゼルシャフト | 殺内部寄生虫剤 |
JP2012107024A (ja) * | 2000-02-22 | 2012-06-07 | Bayer Animal Health Gmbh | 殺内部寄生虫剤 |
US7687533B2 (en) | 2004-03-18 | 2010-03-30 | Pfizer Inc. | N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides |
KR101280511B1 (ko) * | 2004-11-16 | 2013-07-01 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 체내기생충의 수직 감염 예방 |
DE102008022520A1 (de) | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
DE102008030764A1 (de) | 2008-06-28 | 2009-12-31 | Bayer Animal Health Gmbh | Kombination von Amidin-Derivaten mit cyclischen Depsipeptiden |
DE102008031284A1 (de) | 2008-07-02 | 2010-01-07 | Bayer Schering Pharma Aktiengesellschaft | Neue Bekämpfungsmöglichkeit der Giardiose |
DE102008031283A1 (de) | 2008-07-02 | 2010-01-07 | Bayer Schering Pharma Aktiengesellschaft | Neue Bekämpfungsmöglichkeit von durch Trichomonadida hervorgerufenen Krankheiten |
US10959970B2 (en) | 2009-02-16 | 2021-03-30 | Nogra Pharma Limited | Methods of treating hair related conditions |
WO2010102762A1 (de) | 2009-03-10 | 2010-09-16 | Bayer Animal Health Gmbh | Zubereitung auf ölbasis enthaltend anti-protozoische triazine und anthelmintische cyclodepsipeptide |
DE102009012423A1 (de) | 2009-03-10 | 2010-09-16 | Bayer Animal Health Gmbh | Zubereitung auf Ölbasis |
WO2011067272A1 (en) | 2009-12-01 | 2011-06-09 | Syngenta Participations Ag | Insecticidal compounds based on isoxazoline derivatives |
US9609869B2 (en) | 2009-12-01 | 2017-04-04 | Syngenta Crop Protection, Llc | Insecticidal compounds based on isoxazoline derivatives |
US11357231B2 (en) | 2009-12-01 | 2022-06-14 | Syngenta Crop Protection Llc | Insecticidal compounds based on isoxazoline derivatives |
US10750745B2 (en) | 2009-12-01 | 2020-08-25 | Syngenta Crop Protection, Llc | Insecticidal compounds based on isoxazoline derivatives |
US10206400B2 (en) | 2009-12-01 | 2019-02-19 | Syngenta Participations Ag | Insecticidal compounds based on isoxazoline derivatives |
WO2011101402A1 (en) | 2010-02-17 | 2011-08-25 | Syngenta Participations Ag | Isoxazoline derivatives as insecticides |
WO2011101229A1 (en) | 2010-02-22 | 2011-08-25 | Syngenta Participations Ag | Dihydrofuran derivatives as insecticidal compounds |
WO2011104089A1 (en) | 2010-02-25 | 2011-09-01 | Syngenta Participations Ag | Process for the preparation of isoxazoline derivatives |
WO2012028556A1 (en) | 2010-08-31 | 2012-03-08 | Bayer Animal Health Gmbh | Macrocyclic lactones and their use and their combinations with other active substances |
WO2012045700A1 (en) | 2010-10-05 | 2012-04-12 | Syngenta Participations Ag | Insecticidal pyrrolidin-yl-aryl-carboxamides |
WO2012049327A2 (en) | 2010-10-15 | 2012-04-19 | Syngenta Participations Ag | Pesticidal mixtures |
WO2012069366A1 (en) | 2010-11-23 | 2012-05-31 | Syngenta Participations Ag | Insecticidal compounds |
WO2012080376A1 (en) | 2010-12-17 | 2012-06-21 | Syngenta Participations Ag | Insecticidal compounds |
DE102010064245A1 (de) | 2010-12-28 | 2012-06-28 | Bayer Animal Health Gmbh | Makrocylischen Lactone und deren Verwendung und deren Kombinationen mit anderen Wirkstoffen |
WO2012107434A1 (en) | 2011-02-09 | 2012-08-16 | Syngenta Participations Ag | Insecticidal compounds |
WO2012126881A1 (en) | 2011-03-22 | 2012-09-27 | Syngenta Participations Ag | Insecticidal compounds |
WO2012156400A1 (en) | 2011-05-18 | 2012-11-22 | Syngenta Participations Ag | Insecticidal compounds based on arylthioacetamide derivatives |
WO2012163948A1 (en) | 2011-05-31 | 2012-12-06 | Syngenta Participations Ag | Pesticidal mixtures including isoxazoline derivatives |
WO2012163959A1 (en) | 2011-05-31 | 2012-12-06 | Syngenta Participations Ag | Insecticidal compounds |
WO2012175474A1 (en) | 2011-06-20 | 2012-12-27 | Syngenta Participations Ag | 1,2,3 triazole pesticides |
WO2013026724A1 (en) | 2011-08-22 | 2013-02-28 | Syngenta Participations Ag | Dihydrofuran derivatives as insecticidal compounds |
WO2013026726A1 (en) | 2011-08-22 | 2013-02-28 | Syngenta Participations Ag | Dihydrofuran derivatives as insecticidal compounds |
WO2013026930A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Process for the preparation of thietane derivatives |
WO2013026929A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Dihydropyrrole derivatives as insecticidal compounds |
WO2013026931A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Isoxazoline derivatives as insecticidal compounds |
WO2013026933A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Isoxazoline derivatives as insecticidal compounds |
WO2013026695A1 (en) | 2011-08-25 | 2013-02-28 | Syngenta Participations Ag | Isoxazoline derivatives as insecticidal compounds |
WO2013037626A1 (en) | 2011-09-13 | 2013-03-21 | Syngenta Participations Ag | Isothiazoline derivatives as insecticidal compounds |
WO2013050302A1 (en) | 2011-10-03 | 2013-04-11 | Syngenta Participations Ag | Isoxazoline derivatives as insecticidal compounds |
WO2013050261A1 (en) | 2011-10-03 | 2013-04-11 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
EP3366675A1 (en) | 2011-10-03 | 2018-08-29 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
WO2013057624A1 (en) | 2011-10-19 | 2013-04-25 | Ah Usa 42 Llc | Use of aminoacetonitrile derivatives against endoparasites |
US10251932B2 (en) | 2011-12-21 | 2019-04-09 | Bayer Pharma Aktiengesellschaft | Preparations containing amorphous emodepside |
JP2015502377A (ja) * | 2011-12-21 | 2015-01-22 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 非晶質エモデプシド含有製剤 |
RU2651761C2 (ru) * | 2011-12-21 | 2018-04-23 | Байер Интеллектуэль Проперти Гмбх | Композиции, содержащие аморфный эмодепсид |
US9539331B2 (en) | 2011-12-21 | 2017-01-10 | Bayer Intellectual Property Gmbh | Preparations containing amorphous emodepside |
WO2013092558A1 (de) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Zubereitungen enthaltend amorphes emodepsid |
US11753365B2 (en) | 2012-02-09 | 2023-09-12 | Nogra Pharma Limited | Methods of treating fibrosis |
US11046641B2 (en) | 2012-02-09 | 2021-06-29 | Nogra Pharma Limited | Methods of treating fibrosis |
WO2013135674A1 (en) | 2012-03-12 | 2013-09-19 | Syngenta Participations Ag | Insecticidal 2-aryl-acetamide compounds |
WO2013187480A1 (ja) | 2012-06-13 | 2013-12-19 | Meiji Seikaファルマ株式会社 | 新規環状デプシペプチド誘導体およびそれを含んでなる有害生物防除剤 |
EP3441399A1 (en) | 2012-06-13 | 2019-02-13 | Meiji Seika Pharma Co., Ltd. | Novel cyclic depsipeptide derivatives and harmful organism control agents comprising the same |
WO2014001120A1 (en) | 2012-06-25 | 2014-01-03 | Syngenta Participations Ag | Isothiazole derivatives as insecticidal compounds |
WO2014001121A1 (en) | 2012-06-25 | 2014-01-03 | Syngenta Participations Ag | Isothiazole derivatives as insecticidal compounds |
WO2014067838A1 (en) | 2012-10-31 | 2014-05-08 | Syngenta Participations Ag | Insecticidal compounds |
WO2014079935A1 (en) | 2012-11-21 | 2014-05-30 | Syngenta Participations Ag | Insecticidal compounds based on arylthioacetamide derivatives |
WO2014161848A1 (en) | 2013-04-02 | 2014-10-09 | Syngenta Participations Ag | Insecticidal compounds |
WO2014161849A1 (en) | 2013-04-02 | 2014-10-09 | Syngenta Participations Ag | Insecticidal compounds |
WO2015007451A1 (en) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
EP3556744A1 (en) | 2013-12-23 | 2019-10-23 | Syngenta Participations Ag | Insecticidal compounds |
WO2016087593A1 (en) | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
EP3848364A1 (en) | 2015-03-27 | 2021-07-14 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives and intermediates for their preparation |
EP3683213A1 (en) | 2015-03-27 | 2020-07-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2016155831A1 (en) | 2015-04-02 | 2016-10-06 | Syngenta Participations Ag | Isoxazoline-styrene derivatives as insecticidal compounds |
JP2022058535A (ja) * | 2015-05-20 | 2022-04-12 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 駆虫性デプシペプチド化合物 |
JP2018516904A (ja) * | 2015-05-20 | 2018-06-28 | メリアル インコーポレイテッド | 駆虫性デプシペプチド化合物 |
WO2017055473A1 (en) | 2015-10-02 | 2017-04-06 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017072247A1 (en) | 2015-10-28 | 2017-05-04 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017076982A1 (en) | 2015-11-04 | 2017-05-11 | Syngenta Participations Ag | Microbiocidal anilide derivatives |
WO2017093348A1 (en) | 2015-12-02 | 2017-06-08 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017102006A1 (en) | 2015-12-17 | 2017-06-22 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017157962A1 (en) | 2016-03-15 | 2017-09-21 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017162868A1 (en) | 2016-03-24 | 2017-09-28 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017174158A1 (en) | 2016-04-08 | 2017-10-12 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017178549A1 (en) | 2016-04-12 | 2017-10-19 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017178408A1 (en) | 2016-04-15 | 2017-10-19 | Syngenta Participations Ag | Microbiocidal silicon containing aryl derivatives |
WO2017207362A1 (en) | 2016-05-30 | 2017-12-07 | Syngenta Participations Ag | Microbiocidal thiazole derivatives |
WO2017207757A1 (en) | 2016-06-03 | 2017-12-07 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2017220485A1 (en) | 2016-06-21 | 2017-12-28 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018015447A1 (en) | 2016-07-22 | 2018-01-25 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018015449A1 (en) | 2016-07-22 | 2018-01-25 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018015458A1 (en) | 2016-07-22 | 2018-01-25 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018029242A1 (en) | 2016-08-11 | 2018-02-15 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018055133A1 (en) | 2016-09-23 | 2018-03-29 | Syngenta Participations Ag | Microbiocidal tetrazolone derivatives |
WO2018055135A1 (en) | 2016-09-23 | 2018-03-29 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018065414A1 (en) | 2016-10-06 | 2018-04-12 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018158365A1 (en) | 2017-03-03 | 2018-09-07 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018162643A1 (en) | 2017-03-10 | 2018-09-13 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018185013A1 (en) | 2017-04-03 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184982A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184988A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184986A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184985A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184984A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018184987A1 (en) | 2017-04-05 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018185211A1 (en) | 2017-04-06 | 2018-10-11 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2018206419A1 (en) | 2017-05-12 | 2018-11-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2018219825A1 (en) | 2017-06-02 | 2018-12-06 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2019011929A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019011928A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019011926A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019011923A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019012001A1 (en) | 2017-07-12 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019012011A1 (en) | 2017-07-12 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019012003A1 (en) | 2017-07-13 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
WO2019053015A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053027A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053024A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053019A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053016A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053010A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019053026A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
WO2019068812A1 (en) | 2017-10-05 | 2019-04-11 | Syngenta Participations Ag | MICROBIOCIDE PICOLINAMIDE DERIVATIVES |
WO2019068809A1 (en) | 2017-10-05 | 2019-04-11 | Syngenta Participations Ag | MICROBIOCIDE PICOLINAMIDE DERIVATIVES |
WO2019091975A1 (en) | 2017-11-07 | 2019-05-16 | Bayer Animal Health Gmbh | Method for the synthesis of cyclic depsipeptides |
EP3480195A1 (en) | 2017-11-07 | 2019-05-08 | Bayer Animal Health GmbH | Method for the synthesis of cyclic depsipeptides |
WO2019096709A1 (en) | 2017-11-15 | 2019-05-23 | Syngenta Participations Ag | Microbiocidal picolinamide derivatives |
WO2019097054A1 (en) | 2017-11-20 | 2019-05-23 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2019105933A1 (en) | 2017-11-29 | 2019-06-06 | Syngenta Participations Ag | Microbiocidal thiazole derivatives |
WO2019121149A1 (en) | 2017-12-19 | 2019-06-27 | Syngenta Participations Ag | Microbiocidal picolinamide derivatives |
WO2019121394A1 (en) | 2017-12-19 | 2019-06-27 | Syngenta Participations Ag | Polymorphs |
WO2019207062A1 (en) | 2018-04-26 | 2019-10-31 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
WO2019224160A1 (en) | 2018-05-25 | 2019-11-28 | Syngenta Participations Ag | Microbiocidal picolinamide derivatives |
WO2020002331A1 (en) | 2018-06-29 | 2020-01-02 | Syngenta Crop Protection Ag | Microbiocidal oxadiazole derivatives |
WO2020007658A1 (en) | 2018-07-02 | 2020-01-09 | Syngenta Crop Protection Ag | 3-(2-thienyl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as agrochemical fungicides |
WO2020016180A1 (en) | 2018-07-16 | 2020-01-23 | Syngenta Crop Protection Ag | Microbiocidal oxadiazole derivatives |
WO2020025807A1 (en) | 2018-08-03 | 2020-02-06 | Syngenta Crop Protection Ag | Microbiocidal 1,2,5-oxadiazol-3(2h)-one derivatives |
WO2020058207A1 (en) | 2018-09-19 | 2020-03-26 | Syngenta Crop Protection Ag | Microbiocidal quinoline carboxamide derivatives |
WO2020070132A1 (en) | 2018-10-06 | 2020-04-09 | Syngenta Participations Ag | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives |
WO2020070131A1 (en) | 2018-10-06 | 2020-04-09 | Syngenta Participations Ag | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives |
WO2020078732A1 (en) | 2018-10-17 | 2020-04-23 | Syngenta Crop Protection Ag | Microbiocidal oxadiazole derivatives |
WO2020079111A1 (en) | 2018-10-18 | 2020-04-23 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2020109509A1 (en) | 2018-11-30 | 2020-06-04 | Syngenta Participations Ag | Microbiocidal thiazole derivatives |
WO2020109511A1 (en) | 2018-11-30 | 2020-06-04 | Syngenta Crop Protection Ag | Microbiocidal 2-acylamino-thiazole-4-carboxamide derivatives |
US11905232B2 (en) | 2019-02-08 | 2024-02-20 | Nogra Pharma Limited | Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
WO2020165403A1 (en) | 2019-02-15 | 2020-08-20 | Syngenta Crop Protection Ag | Phenyl substituted thiazole derivatives as microbiocidal compounds |
WO2020193387A1 (en) | 2019-03-22 | 2020-10-01 | Syngenta Crop Protection Ag | Fungicidal compounds |
WO2020193618A1 (en) | 2019-03-27 | 2020-10-01 | Syngenta Crop Protection Ag | Microbiocidal thiazole derivatives |
WO2020208095A1 (en) | 2019-04-10 | 2020-10-15 | Syngenta Crop Protection Ag | Microbiocidal picolinamide derivatives |
WO2020239855A1 (en) | 2019-05-29 | 2020-12-03 | Syngenta Crop Protection Ag | Microbiocidal derivatives |
WO2020239853A1 (en) | 2019-05-29 | 2020-12-03 | Syngenta Crop Protection Ag | Microbiocidal derivatives |
WO2020239856A1 (en) | 2019-05-29 | 2020-12-03 | Syngenta Crop Protection Ag | Microbiocidal derivatives |
WO2020239854A1 (en) | 2019-05-29 | 2020-12-03 | Syngenta Crop Protection Ag | Microbiocidal derivatives |
WO2021004968A1 (en) | 2019-07-05 | 2021-01-14 | Syngenta Crop Protection Ag | Microbiocidal picolinamide derivatives |
WO2021009026A1 (en) | 2019-07-12 | 2021-01-21 | Syngenta Crop Protection Ag | Methyl 2-[(4-methoxyimino-tetralin-6-yl]prop-2-enoate derivatives, chromane, isochromane, 6,7,8,9-tetrahydrobenzo[7]annulene, 1h-isobenzofurane and indane analogues thereof, and similar compounds, as agrochemical fungicides |
WO2021028479A1 (en) | 2019-08-14 | 2021-02-18 | Vetoquinol S.A. | Compositions comprising tigolaner for controlling parasites |
WO2021032631A1 (en) | 2019-08-21 | 2021-02-25 | Syngenta Participations Ag | Precision treatment and sowing or planting method and device |
WO2021032633A1 (en) | 2019-08-21 | 2021-02-25 | Syngenta Participations Ag | High precision greenhouse seed and seedling treatment |
WO2021032634A1 (en) | 2019-08-21 | 2021-02-25 | Syngenta Participations Ag | Apparatus and method for reducing dust development in precision drill sowing |
WO2021032630A1 (en) | 2019-08-21 | 2021-02-25 | Syngenta Participations Ag | Sowing device and method for treating seeds during planting |
WO2021032632A1 (en) | 2019-08-21 | 2021-02-25 | Syngenta Participations Ag | Apparatus and method for converting existing sowing equipment |
WO2021204855A1 (en) | 2020-04-08 | 2021-10-14 | Syngenta Crop Protection Ag | Microbiocidal quinoline dihydropyrrolopyrazine derivatives |
WO2021204822A1 (en) | 2020-04-08 | 2021-10-14 | Syngenta Crop Protection Ag | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives |
WO2021204857A1 (en) | 2020-04-08 | 2021-10-14 | Syngenta Crop Protection Ag | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives |
WO2021219775A1 (en) | 2020-04-30 | 2021-11-04 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2021219778A1 (en) | 2020-04-30 | 2021-11-04 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2021219780A1 (en) | 2020-05-01 | 2021-11-04 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2021224102A1 (en) | 2020-05-05 | 2021-11-11 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2021244952A1 (en) | 2020-06-03 | 2021-12-09 | Syngenta Crop Protection Ag | Microbiocidal derivatives |
WO2022058580A1 (en) | 2020-09-21 | 2022-03-24 | Syngenta Crop Protection Ag | Microbiocidal compounds |
WO2022207479A1 (en) | 2021-03-27 | 2022-10-06 | Syngenta Crop Protection Ag | Microbiocidal isonicotinic amide derivatives |
WO2022207665A1 (en) | 2021-03-31 | 2022-10-06 | Syngenta Crop Protection Ag | Microbiocidal quinoline/quinoxaline benzothiazine derivatives |
WO2022223376A1 (en) | 2021-04-20 | 2022-10-27 | Syngenta Crop Protection Ag | Microbiocidal quinoline/quinoxaline isoquinoline derivatives |
WO2023012044A1 (en) | 2021-08-02 | 2023-02-09 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2023089049A2 (en) | 2021-11-19 | 2023-05-25 | Syngenta Crop Protection Ag | Microbiocidal isonicotinic amide derivatives |
WO2023094303A1 (en) | 2021-11-25 | 2023-06-01 | Syngenta Crop Protection Ag | Microbiocidal heterobiaryl amide derivatives |
WO2023094304A1 (en) | 2021-11-25 | 2023-06-01 | Syngenta Crop Protection Ag | Microbiocidal heterobiaryl amide derivatives |
WO2023110869A1 (en) | 2021-12-15 | 2023-06-22 | Syngenta Crop Protection Ag | Microbiocidal bicycle heterocyclic derivatives |
WO2023111215A1 (en) | 2021-12-17 | 2023-06-22 | Syngenta Crop Protection Ag | Microbiocidal pyridine-substituted benzothiazine derivatives |
WO2023110871A1 (en) | 2021-12-17 | 2023-06-22 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2023118011A1 (en) | 2021-12-22 | 2023-06-29 | Syngenta Crop Protection Ag | Microbiocidal aza-heterobiaryl derivatives |
WO2023139166A1 (en) | 2022-01-19 | 2023-07-27 | Syngenta Crop Protection Ag | Methods for controlling plant pathogens |
WO2023148206A1 (en) | 2022-02-02 | 2023-08-10 | Syngenta Crop Protection Ag | Microbiocidal n-amide derivatives |
WO2023166067A1 (en) | 2022-03-02 | 2023-09-07 | Syngenta Crop Protection Ag | Microbiocidal pyridazinone amide derivatives |
WO2023247552A1 (en) | 2022-06-21 | 2023-12-28 | Syngenta Crop Protection Ag | Microbiocidal bicyclic heterocyclic carboxamide derivatives |
WO2024018016A1 (en) | 2022-07-21 | 2024-01-25 | Syngenta Crop Protection Ag | Crystalline forms of 1,2,4-oxadiazole fungicides |
WO2024068655A1 (en) | 2022-09-28 | 2024-04-04 | Syngenta Crop Protection Ag | Fungicidal compositions |
WO2024068656A1 (en) | 2022-09-28 | 2024-04-04 | Syngenta Crop Protection Ag | Fungicidal compositions |
WO2024068947A1 (en) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2024068950A1 (en) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2024089191A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Microbiocidal heterobicyclic dihydrooxadiazine derivatives |
WO2024100069A1 (en) | 2022-11-08 | 2024-05-16 | Syngenta Crop Protection Ag | Microbiocidal pyridine derivatives |
WO2024100115A1 (en) | 2022-11-09 | 2024-05-16 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2024105104A1 (en) | 2022-11-16 | 2024-05-23 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline derivatives |
WO2024115509A1 (en) | 2022-11-29 | 2024-06-06 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline derivatives |
WO2024115512A1 (en) | 2022-11-30 | 2024-06-06 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline derivatives |
Also Published As
Publication number | Publication date |
---|---|
ES2166359T3 (es) | 2002-04-16 |
AU669883B2 (en) | 1996-06-27 |
NZ249588A (en) | 1996-08-27 |
HK1004481A1 (en) | 1998-11-27 |
NL300215I1 (nl) | 2006-03-01 |
DE69331414T2 (de) | 2002-08-08 |
EP0634408A4 (en) | 1995-03-08 |
LU91210I2 (fr) | 2006-11-06 |
JP2874342B2 (ja) | 1999-03-24 |
CN1080932A (zh) | 1994-01-19 |
PT634408E (pt) | 2002-05-31 |
EP0634408B1 (en) | 2002-01-02 |
CA2132199A1 (en) | 1993-09-18 |
CN1039331C (zh) | 1998-07-29 |
ATE211466T1 (de) | 2002-01-15 |
US5514773A (en) | 1996-05-07 |
DE122005000058I1 (de) | 2006-04-27 |
DK0634408T3 (da) | 2002-04-22 |
CA2132199C (en) | 2000-01-18 |
EP0634408A1 (en) | 1995-01-18 |
AU3648393A (en) | 1993-10-21 |
DE69331414D1 (de) | 2002-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993019053A1 (fr) | Derive de depsipeptide, production et utilisation | |
CN1178665C (zh) | 唑系化合物的水溶性前药 | |
CN1066713C (zh) | 茋衍生物和含有它们的药物组合物 | |
WO1995007272A1 (en) | Cyclodepsipeptide compound | |
Walter et al. | Reaction of ruppert’s reagent (TMS-CF3) with Oxazolidinones: Synthesis of protected α-amino trifluoromethylketones | |
CN104370793A (zh) | 吡咯类海洋生物碱Neolamellarin A类似物及其制备方法和应用 | |
EP0428423A2 (fr) | Nouveaux aryloxy alcoyl benzènes, leurs procédés de préparation et les compositions pharmaceutiques en renfermant | |
EP0551034A2 (fr) | Nouvelles céphalosporines comportant en position 7 un radical benzyloxyimino substitué, leur procédé de préparation, leur application comme médicaments | |
CA1204442A (fr) | Procede de preparation de nouveaux derives de la nitrosouree | |
CN112679400A (zh) | Psammaplin A类衍生物及其制备方法和应用 | |
JP2526951B2 (ja) | エリスロマイシンa誘導体およびその製造方法 | |
KR100539047B1 (ko) | 아미노알콜의 제조 방법 | |
Lin et al. | Synthesis of 3‐Halogenated Flavonoids via Electrophile‐Promoted Cyclization of 2‐(3‐Aryl‐2‐propynoyl) anisoles | |
CN1284954A (zh) | 苯并[c]喹嗪衍生物及其作为5α-还原酶抑制剂的用途 | |
US9617274B1 (en) | Synthetic noribogaine | |
CN1204135C (zh) | 具有镇咳活性的1,3-二氧环戊烷 | |
JP2505962B2 (ja) | 新規なビニルカルバメ―ト類 | |
JP3477631B2 (ja) | 1,3−ビス(3−アミノプロピル)−1,1,3,3−テトラオルガノジシロキサンの精製方法 | |
Moriarty et al. | Synthesis and stereochemistry of 2, 5-dimethoxy 3, 6-disubstituted 1, 4-dioxanes obtained from. alpha.-hydroxy dimethyl acetals | |
Jumaah et al. | Crystal structure of (E)-3-(2-hydroxy-4-methylphenyl)-1-(2, 4, 6-trimethoxyphenyl) prop-2-en-1-one | |
Apel | Development and Application of an Organocatalytic [3, 3]-sigmatropic Rearrangement | |
TW202412741A (zh) | 一種製備2-羥乙基胺基己酸酯類化合物方法及其應用 | |
RU2027700C1 (ru) | 7-алкокси-4-окса-1,2,6-тринитратгептантриолы, обладающие кардиотонической активностью | |
Matysiak et al. | Nucleosides. Part LXIII. Acetals as new 2′‐O‐protecting functions for the synthesis of oligoribonucleotides: Synthesis of uridine building blocks and evaluation of their relative acid stability | |
FR2519638A1 (fr) | Derives d'aminopropylaminobleomycine, leurs applications therapeutiques et procede pour leur preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP NO NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08295782 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2132199 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 249588 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993905622 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993905622 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993905622 Country of ref document: EP |